Skip to search formSkip to main contentSkip to account menu

ARRY 142886

Known as: ARRY-142886, ARRY142886 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AZD 6244Pharmacologic Substance
selumetinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
10503Background: PN in NF1 can cause substantial morbidity, and there are no approved medical therapies. In a phase I trial of… 
2015
2015
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
SummaryPurposeKRAS is frequently mutated in non-small cell lung cancers (NSCLC), resulting in activation of the MEK/ERK pathway… 
2013
2013
Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.
4014 Background: Pharmacologic inhibition of MEK leads to enhanced signaling through EGFR with hyperactivation of a parallel… 
2013
2013
Predictive Biomarkers and Personalized Medicine Phase II Trial of MEK Inhibitor Selumetinib ( AZD 6244 , ARRY-142886 ) in Patients with BRAFV 600 E / K-Mutated Melanoma
Purpose: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be… 
2013
2013
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
SummaryThis study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated… 
Highly Cited
2010
Highly Cited
2010
Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines
Selumetinib (AZD6244; ARRY-142886) is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK… 
2010
2010
Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements.
5536 Background: There is no standard treatment for IRPTC. AZD6244 is an oral, small molecule inhibitor of the mitogen-activated… 
2008
2008
Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)
8029 Background: The Raf/MEK/ERK signaling pathway is necessary for oncogenic function, and in NSCLC pts constitutive activation… 
2008
2008
AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy
• No standard of care exists for patients who experience disease progression after treatment with oxaliplatin/irinotecan-based… 
2005
2005
Validation and use of a biomarker for clinical development of the MEK1/2 inhibitor ARRY-142886 (AZD6244)
3075 Background: Optimal transition of a signal transduction inhibitor from discovery into clinical development requires a robust… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)